Follow
Albert Jan van Hoek
Albert Jan van Hoek
Health economist / Infectious disease modeller, RIVM
Verified email at rivm.nl
Title
Cited by
Cited by
Year
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
S Flasche, AJ Van Hoek, E Sheasby, P Waight, N Andrews, C Sheppard, ...
PLoS medicine 8 (4), e1001017, 2011
3172011
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
AJ Van Hoek, N Andrews, PA Waight, J Stowe, P Gates, R George, ...
Journal of Infection 65 (1), 17-24, 2012
2772012
The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy
D Cromer, AJ Van Hoek, M Jit, WJ Edmunds, D Fleming, E Miller
Journal of Infection 68 (4), 363-371, 2014
2642014
Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
AJ Van Hoek, CL Sheppard, NJ Andrews, PA Waight, MPE Slack, ...
Vaccine 32 (34), 4349-4355, 2014
2132014
Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation
M Baguelin, AJ Van Hoek, M Jit, S Flasche, PJ White, WJ Edmunds
Vaccine 28 (12), 2370-2384, 2010
2092010
Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
AJ Van Hoek, N Gay, A Melegaro, W Opstelten, WJ Edmunds
Vaccine 27 (9), 1454-1467, 2009
1752009
Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument
J Luyten, L Bruyneel, AJ Van Hoek
Vaccine 37 (18), 2494-2501, 2019
1742019
Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 …
MH Rozenbaum, EAM Sanders, AJ van Hoek, AGSC Jansen, ...
Bmj 340, 2010
1422010
Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes
AJ Van Hoek, N Andrews, PA Waight, R George, E Miller
PloS one 7 (7), e39150, 2012
1412012
Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England
AJ Van Hoek, A Melegaro, E Zagheni, WJ Edmunds, N Gay
Vaccine 29 (13), 2411-2420, 2011
1212011
The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study
AJ van Hoek, A Underwood, M Jit, E Miller, WJ Edmunds
PloS one 6 (3), e17030, 2011
1202011
The early transmission dynamics of H1N1pdm influenza in the United Kingdom
A Ghani, M Baguelin, J Griffin, S Flasche, AJ Van Hoek, S Cauchemez, ...
PLoS currents 1, 2009
1122009
Lower vaccine uptake amongst older individuals living alone: A systematic review and meta-analysis of social determinants of vaccine uptake
A Jain, AJ Van Hoek, D Boccia, SL Thomas
Vaccine 35 (18), 2315-2328, 2017
1112017
Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
J Southern, N Andrews, P Sandu, CL Sheppard, PA Waight, NK Fry, ...
PLoS One 13 (5), e0195799, 2018
1102018
Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England
D Cromer, AJ Van Hoek, AT Newall, AJ Pollard, M Jit
The lancet Public health 2 (8), e367-e374, 2017
922017
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control
D Thorrington, N Andrews, J Stowe, E Miller, AJ Van Hoek
BMC medicine 16, 1-14, 2018
912018
Modelling the impact of local reactive school closures on critical care provision during an influenza pandemic
T House, M Baguelin, AJ Van Hoek, PJ White, Z Sadique, K Eames, ...
Proceedings of the Royal Society B: Biological Sciences 278 (1719), 2753-2760, 2011
872011
Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
MH Rozenbaum, AJ Van Hoek, D Fleming, CL Trotter, E Miller, ...
Bmj 345, 2012
842012
The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom
AJ Van Hoek, A Melegaro, N Gay, J Bilcke, WJ Edmunds
Vaccine 30 (6), 1225-1234, 2012
822012
Ebola virus disease in the Democratic Republic of the Congo, 1976-2014
A Rosello, M Mossoko, S Flasche, AJ Van Hoek, P Mbala, A Camacho, ...
Elife 4, e09015, 2015
772015
The system can't perform the operation now. Try again later.
Articles 1–20